Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00748657 · OUTCOME

Progression-free Survival

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary · Source last updated 2019-07-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Every other cycle for 6 months; then every 3 months for two years; then every six months for three years; and at any other time if clinically indicated based on symptoms, physical signs suggestive of progressive disease or rising serum tumor maker levels

What was measured

Progression-Free Survival is the period from study entry until disease progression, death or date of last contact.

Analysis population: Eligible and Treated Patients

Groups in this outcome

Bevacizumab

Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bevacizumab36

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Bevacizumab9.3Not reported4.115.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4.1
        upper Limit
        15.0
        value
        9.3
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    units
    Participants
description
Progression-Free Survival is the period from study entry until disease progression, death or date of last contact.
dispersion Type
95% Confidence Interval
groups
  1. description
    Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment
    id
    OG000
    title
    Bevacizumab
param Type
MEDIAN
population Description
Eligible and Treated Patients
reporting Status
POSTED
time Frame
Every other cycle for 6 months; then every 3 months for two years; then every six months for three years; and at any other time if clinically indicated based on symptoms, physical signs suggestive of progressive disease or rising serum tumor maker levels
title
Progression-free Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice